Method for carrying out photodynamic hair epilation

FIELD: medicine.

SUBSTANCE: method involves removing hair from skin area to be subjected to epilation without mechanical injuries being caused to skin integrity 3 days before applying photodynamic hair epilation. Skin is degreased with a preparation containing no alcohol. Pulsating scanning laser radiation is applied to the skin area to be epilated. Radiation wavelength is 800-930 nm and frequency is equal to 140-160 Hz during 5-20 min under radiation power of 4-10 W per pulse and its duration being equal to 50-300 ns. The area to be epilated is covered with photosensitizing cream, gel or ointment containing 0.1-2% by mass of chlorine row photosensitizer selected from a group composed of Photolon, Radachlorine or Photodithazine or 0.1-1% by mass of porphyrin row photosensitizer selected from a group of Photogem, or Photofrin. After having exposed skin area under epilation covered with photosensitizer without light access during 3-6 h, photosensitizer residue is removed from the skin area without injuring epidermis and anesthetic management is carried out when needed. A region on skin surface under epilation is isolated with material radiopaque to laser radiation and the selected skin areas are treated with parallel light beam issued from square, triangular, rectangular, pentagonal or hexagonal shape stencil opening. The stencil edge is moved over the whole skin area under epilation. Wavelength is equal to 661-666 nm when using chlorine row photosensitizer or 630-633 nm when using porphyrin row photosensitizer with radiation power density of 20-80 J/cm2. Epilation region area does not exceed 100 cm2 during single photodynamic epilation session. Photodynamic epilation of the next skin region is carried out after all irritation signs have vanished from the previously treated region.

EFFECT: reduced risk of complications; stable cosmetic results.

4 cl

 

The invention relates to medicine, namely to methods of photodynamic hair removal of unwanted hair.

The known method of laser hair removal, including the preparation of the surface of the skin, containing unwanted hair, holding anesthesiological benefits and impact on the surface of the skin laser radiation (see RF patent №2167625, And 61 In 18/20, 2001).

However, the known method when its use has the following disadvantages:

lack of efficiency of hair removal, especially when removing lanugo, fine and light hair,

- restore hair growth in the period from 2 to 6 months after epilation,

- high risk of damage to the skin, especially in people with dark skin,

- not enough stable functional and cosmetic results.

The objective of the invention is a method of photodynamic hair.

The technical result is the ability to ensure high efficiency of hair removal for any type of hair removed, no risk of damage to the skin, as well as getting a long lasting cosmetic results.

The technical result is achieved due to hair removal using photodynamic therapy. I used the technique of photodynamic therapy allows directed the labour is the substance of unwanted hair on the skin, the basis for this effect is that light-induced chemotherapy. Photodynamic therapy with chlorin photosensitizers or porphyrin series allows you to achieve active selective accumulation of a photosensitizer in the hair follicles of the skin and laser irradiation of a photosensitizer with a specific wavelength causes the activation of the photosensitizer, causing induced photochemical reaction in hair follicles, as a result of which they destroyed. Photosensitizers relatively rapidly excreted from the body and have low toxicity.

The method is as follows. From the surface of the subject epilation skin remove hair without mechanical damage to the integrity of the skin for 3 days before photodynamic hair removal. Provide training subject epilation skin. Degrease the skin area hair removal does not contain alcohol, drug and conduct its scanning laser pulse irradiation with a wavelength of 800-930 nm and a frequency of 140-160 Hz for 5-20 minutes at a power of irradiation 4-10 watts per pulse and its duration 50-300 NS. Then the skin is subject epilation area put photosensitizing cream, gel or ointment containing 0.1-2 wt.% photosensitizer chlorin number, select the tion from the group Photolon, Radachlorin or photoditazine, or 0.1-1 wt.% porphyrin photosensitizer number selected from the group Photohem or Photofrin. Using photosensitizing gel based viscoelastic of hyaluronic acid selected from the group healon, viscoat or gigathlon. The surface area of the skin coated with a photosensitizer closed opaque material and can withstand without access of light within 3-6 hours. Then he removed the remains of the photosensitizer in any way without damaging the epidermis, delimit subject epilation skin impervious to laser irradiation material and conducting laser irradiation of a selected area of the skin parallel light beam through the opening in the stencil square, triangular, rectangular, pentagonal or hexagonal shape, consistently pushing the edge in the edge around the area of hair removal, with wavelength 661-666 nm when using the photosensitizer chlorin number or wavelength 630-633 nm when using porphyrin photosensitizer, with the energy density of the radiation 20 to 80 j/cm2. At the same time for one session of photodynamic therapy process is not more than 100 cm2the area of hair removal. After hair removal provide anti-inflammatory and burns therapy use is the use of wound healing drugs within 3-5 days and epilation in the next part of the skin is carried out after the disappearance of skin irritation previous.

Among the essential features that characterize the way photodynamic epilation, distinctive are

- hair removal for 3 days before photodynamic hair removal with skin with unwanted hair without mechanical damage to the integrity of the skin,

- degreasing of the skin contains no alcohol drug

- laser pulse irradiation area epilation with wavelength 800-930 nm and a frequency of 140-160 Hz for 5-20 minutes at a power of irradiation 4-10 watts per pulse and pulse width 50-300 NS,

- applying to the skin of the epilation photosensitizing cream, gels or ointments containing from 0.1 to 2 wt.% photosensitizer chlorin number selected from the group Photolon, Radachlorin or photoditazine, or from 0.1 to 1 wt.% porphyrin photosensitizer number selected from the group Photohem or Photofrin,

- the use of photosensitizing gel based viscoelastic of hyaluronic acid selected from the group healon, viscoat or giacolone,

closing subject epilation surface area of the skin coated with a photosensitizer before laser radiation opaque material,

- remove residues photosin is debilitator in any way without damaging the epidermis after exposure area epilation without access of light within 3-6 hours,

- the delimitation of the subject of hair removal portion of the surface of the skin does not transmit the laser light material

- conducting laser irradiation of a selected area of the skin parallel light beam through the opening in the stencil square, triangular, rectangular, pentagonal or hexagonal shape, consistently pushing the edge in the edge around the area of hair removal, with wavelength 661-666 nm when using the photosensitizer chlorin number or wavelength 630-633 nm when using porphyrin photosensitizer, with the energy density of the radiation 20 to 80 j/cm2,

treatment in a single session of photodynamic therapy is not more than 100 cm2the area of hair removal,

- implementation of photodynamic epilation next section of the skin after the disappearance of signs of skin irritation previous.

Experimental studies of the proposed method photodynamic epilation in clinical conditions showed high efficiency of the proposed method. Thus was obtained a smooth uncomplicated postoperative period, provided the high efficiency of the epilation with any type of hair, and also received a long lasting cosmetic results.

Implementation of the proposed method photodynamic epilation illustrious is by the following clinical examples.

Example 1. Patient D., 22 received in the Kaluga branch of IRTC "eye microsurgery" diagnosis: excessive growth of bristly hair in the area between the eyebrows.

Conducted photodynamic hair removal of unwanted hair in the area between the eyebrows.

Spent removing hair from the surface of the skin between the eyebrows without mechanical damage to the integrity of the skin for 3 days before photodynamic hair removal. Conducted site preparation epilation. Degreased subject epilation skin area does not contain alcohol, drugs and spent his scanning laser pulse irradiation with a wavelength of 800 nm and a frequency of 160 Hz for 5 minutes when power irradiation 10 W pulse duration of 300 NS. Then on the skin between the eyebrows caused photosensitizing gel based viscoelastic hyaluronic acid, namely viscoat containing 2 wt.% photosensitizer chlorin number of Radachlorin. The surface area of the skin coated with a photosensitizer closed opaque material and has withstood without access to light for 6 hours. Then he removed the remains of the photosensitizer without damaging the epidermis and spent anesthetic manual. Demarcate subject of hair removal the surface area of the skin is not permeable to the laser material and held lasern the e irradiating a selected area of the skin parallel light beam through the opening in the stencil square shape, sequentially moving the edge of the edge around the subject of hair removal area, with a wavelength of 666 nm with an energy density of radiation 80 j/cm2. After hair removal was appointed and held anti-inflammatory and burns therapy using wound-healing drugs for 5 days.

The obtained smooth uncomplicated postoperative course. After 5 days the signs of skin irritation not available. The observation period of 3 months. Unwanted hair in the brow area no. Ensured high efficiency epilation with obtaining long-term and stable cosmetic result.

Example 2. Patient C., 28 years old, he enrolled in the Kaluga branch of IRTC "eye microsurgery" diagnosis: excessive hair growth on the chin.

Conducted photodynamic hair removal on the chin.

Spent removing hair from the surface of the skin of the chin without mechanical damage to the integrity of the skin for 3 days before photodynamic hair removal. Conducted site preparation epilation. Degreased skin does not contain alcohol, drugs and spent his scanning laser pulse irradiation with a wavelength of 930 nm and a frequency of 140 Hz for 20 minutes with the power of irradiation of 4 watts per pulse and its duration is 50 NS. Then the skin podbora the internal field caused photosensitizing cream containing 0.1 wt.% porphyrin photosensitizer series - injected. The surface area of the skin coated with a photosensitizer closed opaque material and has withstood without access of light for 3 hours. Then he removed the remains of the photosensitizer without damaging the epidermis and spent anesthetic manual. Demarcate subject of hair removal the surface area of the skin is not permeable to the laser material and held laser irradiation of a selected area of the skin parallel light beam through the opening in the stencil hexagonal shape, consistently pushing the edge of the edge around the subject of hair removal to skin, with a wavelength of 633 nm, the energy density of the irradiation of 20 j/cm2. After hair removal has appointed and implemented anti-inflammatory and burns therapy using wound-healing drugs for 3 days. Before the next section of the skin was carried out after the disappearance of signs of skin irritation previous.

The obtained smooth uncomplicated postoperative course. After 6 days the inflammation in the skin are missing. The observation period of 4.5 months. The skin on the chin smooth, no hair. Achieved high efficiency of the epilation received is eaten in a long lasting cosmetic results.

1. The way photodynamic hair epilation, including preparation of the surface of the skin with unwanted hair growth, conduction anesthesia and the impact on the surface of the skin to laser radiation, characterized in that for 3 days before photodynamic epilation with subject epilation skin remove hair without mechanical damage to the integrity of the skin, degrease the skin, not containing alcohol, drug, conduct a scanning laser pulse irradiation area epilation with wavelength 800-930 nm and a frequency of 140-160 Hz for 5-20 minutes at a power of irradiation 4-10 watts per pulse and its duration 50-300 NS, then to the skin of the epilation put photosensitizing cream, gel or ointment containing from 0.1 to 2 wt.% photosensitizer chlorin number selected from the group Photolon, Radachlorin or photoditazine, or from 0.1 to 1 wt.% porphyrin photosensitizer number selected from the group Photohem or Photofrin, after exposure subject epilation skin coated with a photosensitizer without access of light within 3-6 h to remove any traces of him photosensitizer without damaging the epidermis, conduct, if necessary, anesthesia allowance, subject to delimit epilation a portion of the surface of the skin do not miss what they laser material and conducting laser irradiation of selected areas of the skin parallel light beam through the opening in the stencil square, triangular, rectangular, pentagonal or hexagonal shape, consistently pushing the edge around the subject of hair removal to skin, with a wavelength of 661-666 nm when using the photosensitizer chlorin number or wavelength 630-633 nm when using porphyrin photosensitizer number, when the energy density of radiation 20-80 j/cm, while for one session of photodynamic therapy process is not more than 100 cm2the area of hair removal, photodynamic epilation next section of the skin is carried out after the disappearance of signs of skin irritation previous.

2. The method according to claim 1, characterized in that the use of photosensitizing gel-based viscoelastic of hyaluronic acid selected from the group healon, viscoat or gigathlon.

3. The method according to claim 1 or 2, characterized in that the laser irradiation subject epilation skin coated with a photosensitizer carry out through the holes in the stencil made from non-permeable to laser irradiation of the material.

4. The method according to claim 1 or 3, characterized in that subject epilation skin area coated with a photosensitizer before laser irradiation closed opaque material.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves sequentially administering ultrasonic inhalations with sodium hydrocarbonate alkaline mineralized and boric mineral water with increased fluorine concentration at aerosol flow speed being equal to 5 l/min during 3 min with following olive oil or other kernel oil inhalation. Then laser radiation therapy is applied to skin above left cubital vein with pulse frequency of 80 Hz and C YII-Th IY reflexogenic segmental zones are treated next to it during 5 min on the left dorsal side at pulse succession frequency being equal to 3000 Hz, pulse power of 2 W alternating it every other day with balneological hydrogen sulfide treatments given to boys at hydrogen sulfide concentration of 50-100 mg/l and to girls at hydrogen sulfide concentration of 25-50 mg/l. The total treatment course is 8 balneological treatments and 10 physiotherapy procedures long.

EFFECT: improved adaptive organism capabilities and its tolerance to physical loads.

3 tbl

FIELD: medicine.

SUBSTANCE: method involves doing vitrectomy, withdrawing posterior hyaline membrane, making radial optical neurotomy, trans-sclerally irradiating ciliary body regions field-by-field between direct muscles in four quadrants 1.5-2 mm far from limb using low intensity laser radiation of wavelength equal to 633 nm at a dose of 2.5 J or wavelength of 890 nm at a dose of 1.2 J. Chlorine row photosensitizer is intravenously introduced and ciliary body regions are trans-sclerally irradiated field-by-field with neighboring fields overlapping by 5% of area between direct muscles in four quadrants 1.5-2 mm far from limb using laser radiation of wavelength corresponding to maximum light emission absorption on photosensitizer part and power density equal to 50-80 J/cm2 5 min later after having introduced the photosensitizer. Another embodiment of the invention involves doing vitrectomy, withdrawing posterior hyaline membrane, making radial optical neurotomy, trans-sclerally irradiating the whole zone of ciliary body field-by-field 1.5-2 mm far from limb using low intensity laser radiation of wavelength equal to 633 nm at a dose of 2.5 J or wavelength of 890 nm at a dose of 1.2 J. Chlorine row photosensitizer is intravenously introduced and ciliary body regions are irradiated field-by-field with neighboring fields overlapping by 5% of area using laser radiation of wavelength corresponding to maximum light emission absorption on photosensitizer part and power density equal to 40-50 J/cm2 5 min later after having introduced the photosensitizer.

EFFECT: dosed action upon ciliary body; reduced risk of traumatic complications; stable ophthalmotonus compensation; improved microcirculation in optic nerve; improved vision function.

2 cl

FIELD: medicine.

SUBSTANCE: method involves applying transpupillary irradiation of intraocular neoplasm with low intensity laser radiation of wavelength equal to 633 nm at a dose of 2.5 J or wavelength of 890 nm at a dose of 1.2 J. Then, chlorine row photosensitizer is intravenously introduced at a dose of 0.8-1.1 mg/kg. Spectral fluorescence diagnostic of photosensitizer accumulation is carried out 15-20 min later in the neoplasm. Intraocular neoplasm fluorescence being observed compared to the surrounding tissue, the neoplasm is transpupillary irradiated using laser radiation of wavelength corresponding to maximum light emission absorption on photosensitizer part and power density equal to 100-120 J/cm2. Then, tunnel is formed in subtenon space and neoplasm thermotherapy is trans-sclerally done.

EFFECT: enhanced effectiveness of treatment; dosed treatment course applied; completely stopped tumor growth.

2 cl

FIELD: medicine.

SUBSTANCE: method involves intrastromally introducing chlorine row photosensitizer into tumor in 0.35-0.5% solution in the amount of 0.1-0.5 ml, intravitreally applying to tumor in 1.0-2.0% gel in the amount of 0.2-0.3 ml and intravenously introducing at a dose of 0.5-0.8 mg/kg. Intravenous laser irradiation with wavelength corresponding to maximum light emission absorption on photosensitizer part is concurrently applied with Intravenous photosensitizer introduction during 10-15 min with power of 20-500 mW. Intravenous laser irradiation being over, spectral fluorescence diagnostic of neoplasm is applied. Intravitreal laser irradiation of neoplasm is carried out with wavelength corresponding to maximum light emission absorption on photosensitizer part under power density of 100-120 J/cm2. Then, intraocular neoplasm is intravitreally removed. Retina is smoothed with perfluororganic compound. Photosensitizer is repeatedly introduced 7-14 days later after removing neoplasm and spectral fluorescence diagnostic is applied. The fluorescent regions are exposed to laser radiation with wavelength corresponding to maximum light emission absorption on photosensitizer part and power density equal to 50-80 J/cm2. The perfluororganic compound is substituted with silicon oil. Intravenous photosensitizer introduction and intravenous laser irradiation of blood are repeated 3 months later.

EFFECT: enabled complete intraocular neoplasm removal; reduced risk of viable tumor cells being retained in operation field or disseminated; reduced risk of relapses and metastases applied; completely stopped tumor growth.

2 cl

FIELD: medicine; cardiology.

SUBSTANCE: method includes magnetic-laser influence of pulse laser radiation onto cubitus. Course of treatment includes 10 procedures with duration of 7 minutes each. First 5 procedures are taken daily and the rest ones - every other day. Laser radiation power density equals to 8,93 mW/mm2, magnetic induction is 50 microtesla. From the first day of treatment, the respiratory gymnastics should be done to work out diaphragm breathing by training. For the purpose, patient moves actively with his/her front abdominal wall when breathing through nose in and when breathing out he/she pulls belly inside through close lips. Breathing frequency equals 3-5-7 times a minute, duration of procedure equals to 13-20 minutes.

EFFECT: improved of adaptive abilities of human body; normalized lipidic exchange; prolonged period of remission.

2 ex, 9 tbl

FIELD: medicine, urology.

SUBSTANCE: one should affect with light-diode radiation, magnetic field rectally onto prostatic projection, carry out micro-enemas of magnetized mineral water, magnetotherapy onto areas of pubis, sacrum and perineum. In case of chronic prostatitis in case of exacerbation one should affect with blue, infrared radiation and magnetic field. In case of chronic prostatitis at the stage of remission - with blue, infrared radiation and magnetic field during the first 3-4 procedures, and then - with red, infrared radiation and magnetic field during the next 5-8 procedures, daily, about 8-12 procedures/course. The method enables to carry out differentiated treatment of chronic prostatitis depending upon the activity of inflammatory process and decrease manifestation of pathological side reactions.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine.

SUBSTANCE: invention proposes a method for inhibition of chorionic neovascularization. Method involves irradiation of undesirable novel vascular reticulum in combination with photosensitive agent (porphyrine) and an anti-angiogenic agent taken among antagonist of phospholipase A2, inhibitor of complex kappa B, inhibitor of the growth hormone, inhibitor of insulin-like growth factor-1, inhibitor of cyclooxygenase II, inhibitor of protein kinase C (stautosporin PKC 412) and inhibitor of angiotensin II. The claimed combined treatment provides potentiation of effect of adjunctive photodynamic therapy in combination with enhanced safety.

EFFECT: improved treatment method.

7 cl

FIELD: medicine.

SUBSTANCE: method involves modeling cystic process by introducing 0.1% Synestrol solution in oil once a week during 35 days and exposing mammary gland to helium-neon laser radiation with wavelength of 633 nm and light guide exit power of 13 mW within 10 min during 8 weeks.

EFFECT: enhanced effectiveness in correcting and treating cystic processes in experimental animal mammary gland.

8 dwg

FIELD: medicine; ophthalmology.

SUBSTANCE: method can be used for treatment of serious deep keratitis. Infiltration of cornea is subject to laser IR thermal therapy at wavelength of 810 nm, radiation power of 1000-1250 mW, diameter of spot in focal plane of 2 to 3 mm, time of exposure is 3 sec. 1 to 3 procedures are carried out with time interval of 3-7 days. Method allows avoiding expressed post-operational astigmatism, coagulating effect and development of deep keratoleukoma.

EFFECT: improved efficiency of treatment.

1 ex

FIELD: medicine.

SUBSTANCE: method involves treating intact tissues adjacent to wound or ulcerative defect and regional neurovascular fascicle projections with defocused laser beam of 1-10 W large power via light guide moving at a rate of 0.5-2.0 cm/s. Wound or ulcerative defect surface is remotely treated in moving light guide at a rate of 1-10 mm/s from periphery to the center scanning the surface in circular or linear mode with laser radiation of 1-10 W power. High intensity laser radiation is used as the laser radiation attached to wavelength of 0.805-1.064 mcm in continuous and pulsating mode.

EFFECT: enhanced effectiveness in stimulating additional biologically active zones and improving blood circulation condition therein; accelerated marginal epithelialization process.

2 cl

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!